Universal Health Services, Inc.

NYSE:UHS Stock Report

Market Cap: US$14.5b

Universal Health Services Valuation

Is UHS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of UHS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: UHS ($229.98) is trading below our estimate of future cash flow value ($588)

Significantly Below Future Cash Flow Value: UHS is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for UHS?

Key metric: As UHS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for UHS. This is calculated by dividing UHS's market cap by their current earnings.
What is UHS's PE Ratio?
PE Ratio10.4x
EarningsUS$1.38b
Market CapUS$14.53b

Price to Earnings Ratio vs Peers

How does UHS's PE Ratio compare to its peers?

The above table shows the PE ratio for UHS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average26.4x
EHC Encompass Health
18.6x10.00%US$10.7b
ENSG Ensign Group
35.6x13.22%US$12.4b
THC Tenet Healthcare
14.7x-2.32%US$20.3b
PACS PACS Group
36.7x24.42%US$6.4b
UHS Universal Health Services
10.4x4.99%US$14.5b

Price-To-Earnings vs Peers: UHS is good value based on its Price-To-Earnings Ratio (10.4x) compared to the peer average (26.4x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does UHS's PE Ratio compare vs other companies in the US Healthcare Industry?

5 CompaniesPrice / EarningsEstimated GrowthMarket Cap
CYH Community Health Systems
0.9x-117.81%US$445.77m
MDCE Medical Care Technologies
3.7xn/aUS$1.02m
NIVF NewGenIvf Group
0.02x44.27%US$351.41k
IMTH AnTix Holdings
0.09xn/aUS$108.15k
UHS 10.4xIndustry Avg. 23.6xNo. of Companies9PE01632486480+
5 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: UHS is good value based on its Price-To-Earnings Ratio (10.4x) compared to the US Healthcare industry average (24.1x).

Price to Earnings Ratio vs Fair Ratio

What is UHS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

UHS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.4x
Fair PE Ratio24.2x

Price-To-Earnings vs Fair Ratio: UHS is good value based on its Price-To-Earnings Ratio (10.4x) compared to the estimated Fair Price-To-Earnings Ratio (24.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst UHS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$229.98
US$251.18
+9.22%
9.72%US$302.00US$190.00n/a17
Feb ’27US$201.26
US$250.35
+24.39%
9.92%US$302.00US$190.00n/a17
Jan ’27US$218.02
US$252.18
+15.67%
9.75%US$302.00US$190.00n/a17
Dec ’26US$239.43
US$248.71
+3.87%
10.63%US$302.00US$190.00n/a17
Nov ’26US$217.01
US$239.81
+10.51%
12.00%US$302.00US$190.00n/a16
Oct ’26US$203.51
US$217.75
+7.00%
13.24%US$280.00US$165.00n/a16
Sep ’26US$181.58
US$218.31
+20.23%
13.52%US$280.00US$165.00n/a16
Aug ’26US$162.98
US$222.69
+36.63%
13.09%US$280.00US$165.00n/a16
Jul ’26US$188.94
US$227.63
+20.48%
9.44%US$280.00US$200.00n/a16
Jun ’26US$190.35
US$225.21
+18.32%
10.42%US$280.00US$186.41n/a16
May ’26US$174.63
US$223.46
+27.96%
10.46%US$280.00US$186.41n/a16
Apr ’26US$187.81
US$228.65
+21.75%
11.02%US$280.00US$186.41n/a16
Mar ’26US$175.25
US$230.95
+31.78%
11.20%US$280.00US$176.21n/a15
Feb ’26US$188.56
US$233.68
+23.93%
12.11%US$274.00US$176.21US$201.2615
Jan ’26US$179.42
US$238.21
+32.77%
9.71%US$274.00US$197.00US$218.0215
Dec ’25US$205.00
US$240.81
+17.47%
8.33%US$274.00US$211.00US$239.4315
Nov ’25US$205.26
US$247.81
+20.73%
8.98%US$275.00US$211.00US$217.0115
Oct ’25US$224.66
US$240.20
+6.92%
7.12%US$274.00US$219.00US$203.5116
Sep ’25US$237.97
US$235.76
-0.93%
7.88%US$267.00US$189.00US$181.5816
Aug ’25US$215.82
US$230.27
+6.69%
8.73%US$256.00US$186.00US$162.9815
Jul ’25US$182.20
US$198.53
+8.96%
9.22%US$236.00US$156.00US$188.9415
Jun ’25US$189.80
US$194.20
+2.32%
7.55%US$226.00US$156.00US$190.3515
May ’25US$170.19
US$189.79
+11.51%
6.50%US$208.00US$156.00US$174.6314
Apr ’25US$175.21
US$188.00
+7.30%
6.87%US$208.00US$156.00US$187.8114
Mar ’25US$171.12
US$178.23
+4.16%
9.81%US$208.00US$144.00US$175.2513
Feb ’25US$163.14
US$162.38
-0.46%
8.54%US$190.00US$140.00US$188.5613
US$251.18
Fair Value
8.4% undervalued intrinsic discount
17
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/24 05:33
End of Day Share Price 2026/02/24 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Universal Health Services, Inc. is covered by 33 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hua HaBaird
Andrew MokBarclays
Adam FeinsteinBarclays